Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients

Biomedicine and Pharmacotherapy

Volumn 58, Issue 10, 2004, Pages 582-587

  Kaya, Ayca ^a   Aydin, Neslihan ^a   Topsever, Pinar ^b   Filiz, Müge ^b   Öztürk, Ali ^a   Daǧar, Arslan ^a   Kilinç, Ebru ^c   Ekmekcioglu, Cem ^d  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b KOCAELI UNIVERSITY   (Turkey)

^c Türkiye Diabet Vakft   (Turkey)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Combination therapy; Efficacy; Obesity; Orlistat; Randomized trial; Sibutramine

Indexed keywords

SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADULT; AMNESIA; ANTHROPOMETRY; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DYNAMIC EXERCISE; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERMENORRHEA; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MORBID OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL ANALYSIS; STEATORRHEA; XEROSTOMIA;

EID: 13844321589     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2004.09.006     Document Type: Article

References (33)

1. J.C. Seidel Epidemiology; definition and classification of obesity P.G. Kopelman M.J. Stock Clinical obesity 1998 Blackwell Science Oxford 10 11
2. World Health Organization 1990 Report of the WHO Study Group: diet, nutrition and prevention of chronic diseases, Geneva: WHO; 1990. WHO Technical Report Series 797.
3. T.B. Van:Itallie Worldwide epidemiology of obesity Pharmacoeconomics 5 1994 1 7
4. World Health Organization obesity epidemic puts millions at risk from related diseases Press Release WHO 46 1997 12
5. WHO MONICA Project Risk Factors Int. J. Epidemiol. 18 1989 S46 S55
6. R.C. Turner The role of obesity in diabetes Int. J. Obes. 16 1992 43 46
7. G.A. Colditz, W.C. Willer, M.J. Stampfer, J.E. Manson, C.H. Hennekens, and R.A. Arky Weight as a risk factor for clinical diabetes in women Am. J. Epidemiol. 132 1990 501 513
8. H.B. Hubert, M. Feinleib, P.M. Mc:Namara, and W.P. Castelli Obesity as independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study Circulation 67 1983 968 977
9. K.M. Rexrode, C.H. Hennekens, W.C. Willet, G.A. Colditz, M.J. Stampfer, and J.W. Rich-Edwards A prospective study of body mass index, weight change and risk of stroke in women JAMA 277 1997 1539 1545
10. WHO 2000. Obesity: preventing and managing the global epidemic. Report of a WHO consultation, Geneva: WHO; 2000. WHO Technical Report Series 894.
11. L.F. Van:Gaal, M.A. Wauters, F.W. Pfeiffer, and I.H. De:Leeuw Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? Int. J. Obes. 22 1998 S38 S40
12. D.M. Garner, and S.C. Wooley Confronting the failure of behavioural and dietary treatments of obesity Clin. Psychol. Rev. 6 1991 58 137
13. C. Hanotin, F. Thomas, S.P. Jones, E. Leutenegger, and P. Drouin Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study Int. J. Obes. 22 1998 31 38
14. E.S. Bush, and S.E. Mayer 5-Hydroxytriptamine serotonin: receptor agonists and antagonists J.G. Hardman L.E. Limbird Goodman & Gilman's the pharmacological basis of therapeutics. 10 ed 2001 Mac-Graw Hill USA 260 290
15. K.H. Lucas, and B. Kaplan-Machlis Orlistat--a novel weight loss therapy Ann. Pharmacother 35 2001 314 328
16. A.J. Scheen, and P.J. Lefebvre Antiobesity pharmacotherapy in the management of type 2 diabetes Diabet Metab Res Rev 16 2000 114 124
17. P.A. Hollander, S.C. Elbein, I.B. Hirsch, B. Kelley, J. Mc:Gill, and T. Taylor Role of orlistat in the treatment of obese patient with type 2 diabetes; a 1-year randomized double-blind study Diabetes Care 21 1998 1288 1301
18. National Institutes of Health National Heart, Lung, and Blood Institute September Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. Evidence Report. NIH Publications 4083 1998 57 80 98/
19. T.N. Bryant Computer software for calculating confidence intervals CIA D.G. Altman D. Machin T.N. Bryant M.J. Gardner Statistics with confidence. 2nd ed 2001 BMJ books Bristol 208 213
20. G.A. Bray, D.H. Ryan, D. Gordon, S. Heidingsfelder, F. Cerise, and K. Wilson A double-blind randomized placebo-controlled trial of sibutramine Obes. Res. 4 1996 263 270
21. G.A. Bray, G.L. Blackburn, J.M. Ferguson, F.L. Greenway, A.K. Jain, and C.M. Mendel Sibutramine produces dose-related weight loss Obes. Res. 7 1999 189 198
22. E. Muls, J. Kolanowski, A. Scheen, L. Van:Gaal ObelHyx Study Group The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolaemia: a randomized, double blind, placebo-controlled, multicentre study Int. J. Obes. Relat. Metab. Disorder 25 2001 1713 1721
23. S. O'Meara, R. Riemsma, L. Shirran, L. Mather, and G. Ter:Riet A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity Health Technol. Assess. 5 2001 1 81
24. A. Gokcel, Y. Gumurdulu, H. Karakose, E. Melek:Ertorer, N. Tanaci, and N. Bascil:Tutuncu Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity Diabet. Res. Metab. 4 2002 49 55
25. T.A. Wadden, R.I. Berkowitz, L.G. Womble, D.B. Sarwer, M.E. Arnold, and C.M. Steinberg Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial Obes. Res. 8 2000 431 437
26. M.E. Lean Sibutramine--a review of clinical efficacy Int. J. Obes. 21 1997 530 536
27. W.P. James, A. Astrup, N. Finer, J. Hilsted, P. Kopelman, S. Rössner For the STORM Study Group effects of sibutramine on weight maintenance after weight loss: a randomized trial Lancet 356 2000 2119 2125
28. M. Apfelbaum, P. Vague, O. Ziegler, C. Hanotin, F. Thomas, and E. Leutenegger Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine Am. J. Med. 106 1999 179 184
29. C.A. Luque, and J.A. Rey Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity Ann. Pharmacother. 33 1999 968 978
30. N. Finer, W.P. James, P.G. Kopelman, M.E. Lean, and G. Williams One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor Int. J. Obes. Relat. Metab. Disord. 24 2000 306 313
31. L.F. Van:Gaal, J.I. Broom, G. Enzi, and H. Toplak Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat dose-ranging study group Eur. J. Clin. Pharmacol. 54 1998 125 132
32. J.H. Zavoral Treatment with orlistat reduces cardiovascular risk in obese patients J. Hypertens. 16 1998 2013 2017
33. L. Sjostrom, A. Rissanen, T. Andersen, M. Boldrin, A. Golay, and H.P. Koppeschaar Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicenter Orlistat Study Group Lancet 352 1998 167 172